Mirtaz 15 mg Tab. 15mg

Tablet

Pack Size : 10 Tablet x 1 Strip

Generics : Mirtazapine

Manufacturer : Square Pharmaceuticals Ltd.

Best Price * TK 100.00

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Mirtaz 15 mg Tab Sun Pharmaceutical (Bangladesh) Ltd.

Tk 10.00

Tablet Mitaprex 15 mg Tab Incepta Pharmaceuticals Ltd.

Tk 8.00

Tablet mitaprex 30 mg Incepta Pharmaceuticals Ltd.

Tk 15.00

Tablet Mitrazin Tab. - 15 MG General Pharmaceuticals Ltd.

Tk 8.05

Tablet MONTEX - 10 MG Ibn Sina Pharmaceutical Ind. Ltd.

Tk 16.00

More Information About - Mirtaz 15 mg Tab. 15mg

Description

Generic Name

Mirtazapine

Precaution

Epilepsy or history of seizures; avoid completely in unstable cases. Hepatic or renal impairment, cardiac disorders e.g. conduction disturbances, angina pectoris, recent MI. Hypotension, DM, psychoses, history of bipolar disorder. Stop treatment if jaundice develops. Micturition disturbances, angle-closure glaucoma, raised intraocular pressure. Monitor patient for signs of bone marrow depression. Monitor patient for suicidal tendency. Avoid abrupt withdrawal. May impair ability to drive or operate machinery. Pregnancy and lactation. Elderly. Lactation: Avoid

Indication

Depression, Major depressive disorder

Contra Indication

Mirtazapine Tablets are contraindicated in patients with a known hypersensitivity to mirtazapine or to any of the excipients.

Dose

N/A

Side Effect

>10% Somnolence (54%),Weight gain (>7% increase in <49% of pediatric patients),Xerostomia (25%),Increased appetite (17%),Constipation (13%) 1-10% Asthenia (8%),lWeakness (8%),Weight gain (>7% increase in 8% of adults),Dizziness (7%),Serum TGs increased (6%),Dream disorder (4%),Disturbance in thinking (3%),ALT increased (2%),Peripheral edema (2%),Myalgia (2%),Confusion (2%),Urinary frequency (2%),Tremor (2%),Back pain (2%),Dyspnea (1%) <1% Mania (0.2%),Grand mal seizure (less than 0.1%) Frequency Not Defined Depression exacerbation,Status epilepticus,Suicidal thoughts, suicide (rare),Agranulocytosis,Neutropenia

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Mirtazapine, a piperazinoazepine tetracyclic antidepressant, enhances noradrenergic and serotonergic activity through blockade of central presynaptic adrenergic alpha 2-receptors.

Interaction

Potentiation of sedative effects with alcohol or benzodiazepines. Increased plasma levels with potent CYP3A4 inhibitors (e.g. HIV-protease inhibitors, azole antifungals including ketoconazole, erythromycin, nefazodone). Reduced plasma levels with carbamazepine and other inducers of CYP3A4. Increased bioavailability with cimetidine. Potentially Fatal: Do not use with or within 2 wk of stopping an MAOI; at least 1 wk should elapse between discontinuing mirtazapine and initiating any drug which may provoke a serious reaction (e.g. phenelzine).

Pregnancy Category Note

Pregnancy There are no adequate and well-controlled studies in pregnant women Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed Animal studies Reproduction studies in pregnant rats and rabbits at doses up to 100 mg/kg and 40 mg/kg, respectively (20 and 17 times the maximum recommended human dose [MRHD] on an mg/m2 basis, respectively), have revealed no evidence of teratogenic effects However, in rats, there was an increase in postimplantation losses in dams treated with mirtazapine Lactation May be excreted in breast milk; caution advised

Adult Dose

Oral Depression Adult: Initially, 15 mg daily; may be increased gradually depending on clinical response. Change dose at intervals of at least 1-2 wk. Usual effective dose: 15-45 mg daily given as single dose, preferably at bedtime, or in 2 divided doses. Elderly Depression 7.5 mg/day PO qHS; increase by 7.5-15 mg/day no more frequently than q1-2Weeks; not to exceed 45 mg/day Alzheimer Dementia-related Depression 7.5 mg/day PO qHS; increase by 7.5-15 mg/day no more frequently than q1-2Weeks; not to exceed 60 mg/day Hepatic impairment: Clearance is reduced; monitor closely

Child Dose

Safety and efficacy not established

Renal Dose

Renal impairment (CrCl <39 mL/min): Clearance is reduced; monitor closely

Administration

May be taken with or without food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.